Landscape Capital Management
TCRX icon

Landscape Capital Management’s TScan Therapeutics TCRX Stock Holding History

Landscape Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-25,864
Closed -$25.3K – 831
2026
Q2 		$25.3K Buy
+25,864
New +$27.6K ﹤0.01% 623

Other funds holding TCRX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $741K AUM 2.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Landscape Capital Management's TCRX Position: Q3 2026 in Review

Landscape Capital Management sold out of TScan Therapeutics (TCRX) in Q3 2026, closing a stake of 25,864 shares — an estimated $25.3K sold.

Landscape Capital Management first reported a position in TCRX in Q2 2026 and held it in 1 quarter. The position peaked at $25.3K in Q2 2026. 33 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.

  • Landscape Capital Management reported no remaining TScan Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Landscape Capital Management sold 25,864 TScan Therapeutics shares in Q3 2026, an estimated $25.3K.
  • Landscape Capital Management first reported a position in TScan Therapeutics in Q2 2026 and held it in 1 quarter.
  • Landscape Capital Management's TScan Therapeutics position peaked at $25.3K in Q2 2026.
  • 33 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.

Based on Landscape Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.